Title: ARID1A Deficiency Promotes Progression and Potentiates Therapeutic Antitumour
Immunity in Hepatitis B virus-related Hepatocellular Carcinoma
Version: 3 Date: 03 Jun 2023
Reviewer's report:
1. Whether the HCC patients included in this study are HBsAg positive patients, and whether
the patients with ARID1A Deficiency are patients with Hepatitis B-associated liver cancer#
2. Whether this study can only consider HBsAg positive patients in the selection of patients
included in the public database. The reason is that HBsAg clearance is the standard of clinical
cure of hepatitis B.
3. Whether the icon fonts of some charts should be adjusted to the same size fonts.
4. Regarding the selection of cell lines, could the researchers consider choosing hepatitis B
related cell lines, such as Huh7 and HepG2 2.2.15? Among them, Huh7 can be used only after
transfection with hepatitis B related plasmid.
5. English expression may need to be polished by professional personnel.
Title: ARID1A Deficiency Promotes Progression and Potentiates Therapeutic Antitumour
Immunity in Hepatitis B virus-related Hepatocellular Carcinoma
Version: 3 Date: 03 Jun 2023
Reviewer's report:
1. Whether the HCC patients included in this study are HBsAg positive patients, and whether
the patients with ARID1A Deficiency are patients with Hepatitis B-associated liver cancer#
2. Whether this study can only consider HBsAg positive patients in the selection of patients
included in the public database. The reason is that HBsAg clearance is the standard of clinical
cure of hepatitis B.
3. Whether the icon fonts of some charts should be adjusted to the same size fonts.
4. Regarding the selection of cell lines, could the researchers consider choosing hepatitis B
related cell lines, such as Huh7 and HepG2 2.2.15? Among them, Huh7 can be used only after
transfection with hepatitis B related plasmid.
5. English expression may need to be polished by professional personnel.
Please review this paper.
user
Title: ARID1A Deficiency Promotes Progression and Potentiates Therapeutic Antitumour
Immunity in Hepatitis B virus-related Hepatocellular Carcinoma
Version: 3 Date: 03 Jun 2023
Reviewer's report:
1. Whether the HCC patients included in this study are HBsAg positive patients, and whether
the patients with ARID1A Deficiency are patients with Hepatitis B-associated liver cancer#
2. Whether this study can only consider HBsAg positive patients in the selection of patients
included in the public database. The reason is that HBsAg clearance is the standard of clinical
cure of hepatitis B.
3. Whether the icon fonts of some charts should be adjusted to the same size fonts.
4. Regarding the selection of cell lines, could the researchers consider choosing hepatitis B
related cell lines, such as Huh7 and HepG2 2.2.15? Among them, Huh7 can be used only after
transfection with hepatitis B related plasmid.
5. English expression may need to be polished by professional personnel.
assistant